F10 and lung disorder: In this cohort study of 106 044 patients with nonvalvular atrial fibrillation without preexisting lung disease, 64 555 patients received factor Xa (FXa) inhibitors, 22 501 received dabigatran, and 18 988 received warfarin at baseline.